236 related articles for article (PubMed ID: 18565904)
1. Osteosarcoma: the same old drugs or more?
Bielack SS; Marina N; Ferrari S; Helman LJ; Smeland S; Whelan JS; Reaman GH
J Clin Oncol; 2008 Jun; 26(18):3102-3; author reply 3104-5. PubMed ID: 18565904
[No Abstract] [Full Text] [Related]
2. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation.
Jaffe N; Patel SR; Benjamin RS
Hematol Oncol Clin North Am; 1995 Aug; 9(4):825-40. PubMed ID: 7490244
[TBL] [Abstract][Full Text] [Related]
5. Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
Miser JS; Pritchard DJ; Rock MG; Shives TC; Gilchrist GS; Smithson WA; Arndt CA; Edmonson JH; Schaid DJ
Cancer Treat Res; 1993; 62():333-8. PubMed ID: 8096748
[No Abstract] [Full Text] [Related]
6. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma.
Weiner MA; Harris MB; Lewis M; Jones R; Sherry H; Feurer EJ; Johnson J; Lahman E
Cancer Treat Rep; 1986 Dec; 70(12):1431-2. PubMed ID: 3466693
[No Abstract] [Full Text] [Related]
7. [Neoadjuvant treatment in osteosarcomas].
Kalifa C; Brugières L; Le Deley MC
Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
[TBL] [Abstract][Full Text] [Related]
8. [Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
Orthopade; 2013 Dec; 42(12):1072. PubMed ID: 24482827
[No Abstract] [Full Text] [Related]
9. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
10. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.
Maki RG
J Clin Oncol; 2012 Jun; 30(17):2033-5. PubMed ID: 22565001
[No Abstract] [Full Text] [Related]
12. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for osteosarcoma of the extremities: the Rizzoli Institute experience.
Bacci G; Avella M; Picci P; Ruggieri P; Biagini R; Ferruzzi A; Casadei R; Caldora P; Campanacci M
Chir Organi Mov; 1990; 75(1 Suppl):57-9. PubMed ID: 2249559
[No Abstract] [Full Text] [Related]
14. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
15. Extraskeletal osteosarcoma of the breast in an adolescent girl.
Zils K; Ebner F; Ott M; Müller J; Baumhoer D; Greulich M; Rehnitz D; Rempen A; Schaetzle S; Wilhelm M; Bielack S
J Pediatr Hematol Oncol; 2012 Aug; 34(6):e261-3. PubMed ID: 22246152
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate.
Stine KC; Saylors RL; Saccente S; Becton DL
Med Pediatr Oncol; 2003 Jul; 41(1):77-8. PubMed ID: 12764753
[No Abstract] [Full Text] [Related]
17. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
Saeter G; Wiebe T; Wiklund T; Monge O; Wahlqvist Y; Engström K; Forestier E; Holmström T; Stenwig AE; Willén H; Brosjö O; Follerås G; Alvegård TA; Strander H
Acta Orthop Scand Suppl; 1999 Jun; 285():74-82. PubMed ID: 10429627
[No Abstract] [Full Text] [Related]
19. Epithelioid osteosarcoma of the jaw.
Cozza R; Devito R; De Ioris MA; Zama M; Boldrini R; Fidani P; Donfrancesco A
Pediatr Blood Cancer; 2009 Jul; 52(7):877-9. PubMed ID: 19202567
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of osteogenic sarcoma].
Kalifa C; Vanel D; Lemerle J
Rev Chir Orthop Reparatrice Appar Mot; 1985; 71(7):429-34. PubMed ID: 3911312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
